Cancer Genetics Inc (CGIX)-Medical Equipment-Deals and Alliances Profile

Cancer Genetics Inc (CGIX)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME259459D
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostics products and services in oncology areas. The company offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. Its oncology tests and laboratory services offer critical genomic information to healthcare professionals, biopharma companies, and cancer centers. CGI's clinical services include expand DX, test menu, complete program, and summation report. The company offers a range of pharmacogenomics testing services for clinical oncologists, cancer centers, and research institutions, and for biotech and biopharma customers. It works in research collaboration with cancer centers to develop and validate proprietary tests. CGI is headquartered in Rutherford, New Jersey, the US.

Cancer Genetics Inc (CGIX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company financial deals that enable you to understand the company expansion/divestiture and fund requirements

The profile enables you to analyze the company financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company business segments' expansion / divestiture strategy

The profile presents deals from the company core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

Cancer Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

Cancer Genetics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9

Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

Cancer Genetics Inc, Medical Equipment, Deal Details 11

Asset Purchase 11

Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11

Partnerships 12

Cancer Genetics Enters into Partnership with Mendel Health 12

Cancer Genetics Enters into Agreement with Lantern Pharma 13

Cancer Genetics Partners with ApoCell for ApoStream 14

Cancer Genetics Partners with H3 Biomedicine 14

Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 15

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 16

Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 16

Equity Offering 17

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 17

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 18

Cancer Genetics Raises USD12 Million in Public Offering of Shares 19

Cancer Genetics Completes Public Offering Of Shares For US$46 Million 21

Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 22

Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 23

Cancer Genetics Completes IPO For US$7 Million 24

Cancer Genetics Inc-Key Competitors 27

Key Employees 28

Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Strategy And Business Planning 30

Apr 03, 2017: Cancer Genetics and Mendel Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care 30

Feb 05, 2016: Cancer Genetics Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota 31

Financial Announcements 32

May 11, 2017: Cancer Genetics Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability 32

Mar 23, 2017: Cancer Genetics Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update 34

Nov 10, 2016: Cancer Genetics Announces Strong Third Quarter with 68% Year over Year Revenue Growth and Highlights Path to Future Profitability 36

Aug 09, 2016: Cancer Genetics Reports Second Quarter 2016 Financial Results and Provides Company Updates 38

May 10, 2016: Cancer Genetics Announces 39% Revenue Increase and Provides Recent Company Highlights 40

Mar 10, 2016: Cancer Genetics Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update 42

Corporate Communications 43

Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance 43

Product News 44

Jun 02, 2017: Cancer Genetics to Present at the 7th Annual LD Micro Invitational 44

Mar 13, 2017: Cancer Genetics to Present at A Future Without Cancer Conference on Friday, March 17 45

Jan 21, 2016: Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients 46

Jan 06, 2016: Cancer Genetics to Present Results of Collaborative Renal Biopsy and Clear Cell Renal Cell Carcinoma Studies at the 2016 Genitourinary Cancer Symposium 47

Other Significant Developments 48

Jan 06, 2017: Cancer Genetics Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions 48

Jun 02, 2016: Cancer Genetics Partners with ArcherDX to Offer Archer NGS Assays as a Sequencing Service for Biotech and Pharma 49

May 04, 2016: Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

Cancer Genetics Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

Cancer Genetics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

Cancer Genetics Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

Cancer Genetics Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9

List of Tables

Cancer Genetics Inc, Medical Equipment, Key Facts, 2016 1

Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

Cancer Genetics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6

Cancer Genetics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7

Cancer Genetics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8

Cancer Genetics Inc, Deals By Market, 2011 to YTD 2017 9

Cancer Genetics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10

Cancer Genetics Acquires Assets of Response Genetics for USD14 Million 11

Cancer Genetics Enters into Partnership with Mendel Health 12

Cancer Genetics Enters into Agreement with Lantern Pharma 13

Cancer Genetics Partners with ApoCell for ApoStream 14

Cancer Genetics Partners with H3 Biomedicine 14

Cancer Genetics Enters into Distribution Agreement with Sayre Therapeutics 15

Cancer Genetics Enters into Co-Development Agreement with Columbia University Medical Center 16

Cancer Genetics Italia Enters Into Distribution Agreement With Nikon Instruments 16

Cancer Genetics to Raise USD5.5 Million in Private Placement of Shares and Warrants 17

Cancer Genetics Raises USD5 Million in Private Placement of Shares and Warrants 18

Cancer Genetics Raises USD12 Million in Public Offering of Shares 19

Cancer Genetics Completes Public Offering Of Shares For US$46 Million 21

Cancer Genetic Announces Public Offering Of Common Stock For Up To US$50 Million 22

Cancer Genetics Completes Underwriters' Exercise Of Partial Over-Allotment Option For Public Offering Of Shares For US$16 Million 23

Cancer Genetics Completes IPO For US$7 Million 24

Cancer Genetics Inc, Key Competitors 27

Cancer Genetics Inc, Key Employees 28

Cancer Genetics Inc, Other Locations 29

Cancer Genetics Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cancer Genetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16235
Site License
USD 500 INR 32470
Corporate User License
USD 750 INR 48705

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com